6′-Chloro-7- or 9-(2,3-dihydro-5H-4,1-benzoxathiepin-3-yl)-7H- or 9H-purines and their corresponding sulfones as a new family of cytotoxic drugs

Tetrahedron

Volumn 63, Issue 1, 2007, Pages 183-190

  Núñez, María C ^a   Rodríguez Serrano, Fernando ^b   Marchal, Juan A ^b   Caba, Octavio ^c   Aránega, Antonia ^c   Gallo, Miguel A ^a   Espinosa, Antonio ^a   Campos, Joaquín M ^a  

^a UNIVERSITY OF GRANADA   (Spain)

^b Facultad de CC Experimentales   (Spain)

^c UNIVERSITY OF GRANADA   (Spain)

Author keywords

Antitumour compounds; Benzoxathiepins; Purines; Pyrimidines

Indexed keywords

1 (2,3 DIHYDRO 5H 4,1 BENZOXATHIEPIN 3 YL) 5 BROMOURACIL; 1 (2,3 DIHYDRO 5H 4,1 BENZOXATHIEPIN 3 YL) 5 FLUOROURACIL; 1 (2,3 DIHYDRO 5H 4,1 BENZOXATHIEPIN 3 YL) 5 TRIFLUOROMETHYLURACIL; 1 [2 (2 HYDROXYMETHYLPHENYLTHIO) 1 METHOXYETHYL]URACIL; 6' CHLORO 7 (1,1 DIOXO 2,3 DIHYDRO 5H 4,1 BENZOXATHIEPIN 3 YL) 7H PURINE; 6' CHLORO 7 (2,3 DIHYDRO 5H 4,1 BENZOXATHIEPIN 3 YL) 7H PURINE; 6' CHLORO 7 [1,1 DIOXO 2 (2 HYDROXYMETHYLPHENYLTHIO) 1 METHOXYPHENYLTHIO] 1 METHOXY 7H PURINE; 6' CHLORO 9 (1 OXO 2,3 DIHYDRO 5H 4,1 BENZOXATHIEPIN 3 YL) 9H PURINE; 6' CHLORO 9 (1,1 DIOXO 2,3 DIHYDRO 5H BENZOXATHIEPIN 3 YL) 9H PURINE; 6' CHLORO 9 (2,3 DIHYDRO 5H 4,1 BENZOXATHIEPIN 3 YL) 9H PURINE; 6' CHLORO 9 [1,1 DIOXO 2 (2 HYDROXYMETHYLPHENYLTHIO) 1 METHOXYETHYL] 9H PURINE; 6' CHLORO 9 [2 (2,3 HYDROXYMETHYLPHENYLTHIO)1 METHOXYETHYL]PURINE; 6' METHOXY 9 (2,3 DIHYDRO 5H 4,1 BENZOXATHIEPIN 3 YL) 9H PURINE; CELECOXIB; FLUOROURACIL; PURINE DERIVATIVE; ROFECOXIB; URACIL DERIVATIVE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; COLON CANCER; CONTROLLED STUDY; DRUG ACTIVITY; DRUG CYTOTOXICITY; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; INTESTINE EPITHELIUM; INTESTINE EPITHELIUM CELL; ISOMER; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 37849186647     PISSN: 00404020     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tet.2006.10.023     Document Type: Article

References (24)

1. Saniger E., Campos J., Entrena A., Marchal J.A., Súarez I., Aránega A., Choquesillo D., Niclós J., Gallo M.A., and Espinosa A. Tetrahedron 59 (2003) 5457
2. Campos J., Saniger E., Marchal J.M., Aiello S., Suárez I., Boulaiz H., Aránega A., Gallo M.A., and Espinosa A. Curr. Med. Chem. 12 (2005) 1423
3. Núñez M.C., Entrena A., Rodríguez-Serrano F., Marchal J.A., Aránega A., Gallo M.A., Espinosa A., and Campos J.M. Tetrahedron 61 (2005) 10363
4. Matsuo S., Tanako S., Yamashita J., and Ogawa M. Anticancer Res. 12 (2000) 1575
5. Trouet A., Passioukov A., Derpooten K.V., Fernandez A.M., Abarca-Quinones J., Baurian R., Lobl T.J., Oliyai C., and Dubois V. Cancer Res. 61 (2001) 2843
6. For the numbering of the compounds, the atoms of the benzoxathiepin ring are tagged with numbers without primes, while those of the pyrimidine and purine bases are numbered with primes (′).
7. 3 hybridized carbon bonded to oxygen and to nitrogen are known as O,N-acetals or hemiaminals.
8. Nomura M., Endo K., Shuto S., and Matsuda A. Tetrahedron 55 (1999) 14847
9. Danel K., Larsen E., Pedersen E.B., Vestergaard B.F., and Nielsen C. J. Med. Chem. 39 (1996) 2427
10. Bohringer M., Roth H.-J., Hunziker J., Gobel M., Rishman R., Giger A., Schweizer B., Schreiber J., Leumann C., and Eschenmoser A. Helv. Chim. Acta 75 (1992) 1416
11. Gómez J.A., Trujillo M.A., Campos J., Gallo M.A., and Espinosa A. Tetrahedron 54 (1998) 13295
12. Campos J., Domínguez J.F., Gallo M.A., and Espinosa A. Curr. Pharm. Des. 6 (2000) 1797
13. Choi W.-B., Wilson L.J., Yeola S., and Liotta D.C. J. Am. Chem. Soc. 113 (1991) 9377
14. Vorbrüggen H., and Ruh-Pohlenz C. Synthesis of Nucleosides. In: Paquette L.A. (Ed). Organic Reactions Vol. 55 (2000), Wiley, New York, NY 1-630
15. 4 and MeCN at room temperature, while the N-9 glycosylated products were obtained from the same purines, using TMSOTf and refluxing 1,2-dichloroethane.
16. Khanapure S.P., Garvey D.S., Young D.V., Ezawa M., Earl R.A., Gaston R.D., Fang X., Murty M., Martino A., Shumway M., Trocha M., Marek P., Tam S.W., Janero D.R., and Letts L.G. J. Med. Chem. 46 (2003) 5484
17. Matteucci M., Bhalay G., and Bradley M. Org. Lett. 5 (2003) 235
18. Díaz-Gavilán M., Gómez-Vidal J.A., Entrena A., Gallo M.A., Espinosa A., and Campos J.M. J. Org. Chem. 71 (2006) 1043
19. Gómez J.A., Campos J., Marchal J.A., Trujillo M.A., Melguizo C., Prados J., Gallo M.A., Aránega A., and Espinosa A. Tetrahedron 53 (1997) 7319
20. Schnall S., and Macdonald J.S. In: Macdonald J.S., Haller D.G., and Mayer R.J. (Eds). Manual of Oncologic Therapeutics (1995), J.B. Lippincott, Philadelphia, PA 170-184
21. Palomer A., Cabré F., Pascual J., Campos J., Trujillo M.A., Entrena A., Gallo M.A., García L., Mauleón D., and Espinosa A. J. Med. Chem. 45 (2002) 1402
22. Campos, J. M.; Espinosa, A.; Gallo, M. A.; Gómez-Vidal, J. A.; Núñez, M. C.; Aránega, A.; Marchal, J. A.; Rodríguez-Serrano, F. Spanish Patent Application No. P200601538, 2006.
23. Wilker W., Leibfritz D., Kerssebaum R., and Bermel W. Magn. Reson. Chem. 31 (1993) 287
24. Díaz-Gavilán M., Rodríguez-Serrano F., Gómez-Vidal J.A., Marchal J.A., Aránega A., Gallo M.A., Espinosa A., and Campos J.M. Tetrahedron 60 (2004) 11547